⌕
Dianthus Therapeutics · DNTH · Nasdaq
Tenet 64 · Solid
Compare
$91.81−0.72%At closeTenet 64 · Solid
$91.81−0.67 (−0.72%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Dianthus Therapeutics (DNTH) Stock

Dianthus Therapeutics (DNTH) closed at $91.81 on Nov 13, 2026; its Tenet Score is 64 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

26 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$91.81
Nov 13, 2026
Market cap
$5.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
34.29 – 117.88
low → high
Tenet Score
64/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Dianthus Therapeutics Inc scores 64/100. Solid. Strongest on financial health versus 409 Healthcare peers. Insufficient inputs: Tenet 64 is built from 3 of 4 pillars, from 45% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=409
64/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
50
Quality
46
Health
95
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityDHealthAGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
4.2×
price to book value
P/S
1,817.9×
price to fiscal 2025 sales
ROE
−23%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
pre_revenue
Current ratio
30.02
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Dianthus Therapeutics Inc

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibo…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 89 US ETFs · top wrappers by weightSee all ETFs holding DNTH →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Dianthus Therapeutics in?

Dianthus Therapeutics is in the Healthcare sector and the Drugs industry.

What is Dianthus Therapeutics' Tenet Score?

Dianthus Therapeutics' Tenet Score is 64 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.